Research Publications

Arthritis medicines and cardiovascular events--"house of coxibs".

Topol EJ

Variability in platelet responsiveness to clopidogrel among 544 individuals.

Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ

Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model.

Wang K, Tarakji K, Zhou Z, Zhang M, Forudi F, Zhou X, Koki AT, Smith ME, Keller BT, Topol EJ, Lincoff AM, Penn MS

Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials.

Labinaz M, Mathias J, Pieper K, Granger CB, Lincoff AM, Moliterno DJ, Van de Werf F, Simes J, White HD, Simoons ML, Califf RM, Topol EJ, Armstrong PW, Harrington RA

A robust hybrid between genetic algorithm and support vector machine for extracting an optimal feature gene subset.

Li L, Jiang W, Li X, Moser KL, Guo Z, Du L, Wang Q, Topol EJ, Wang Q, Rao S

Transcription factor MEF2A mutations in patients with coronary artery disease.

Bhagavatula MR, Fan C, Shen GQ, Cassano J, Plow EF, Topol EJ, Wang Q

The sad story of Vioxx, and what we should learn from it.

Karha J, Topol EJ

Impact of female sex on outcome after percutaneous coronary intervention.

Chiu JH, Bhatt DL, Ziada KM, Chew DP, Whitlow PL, Lincoff AM, Ellis SG, Topol EJ

Risk reduction with long-term clopidogrel following percutaneous coronary intervention.

Steinhubl SR, Topol EJ

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.

Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ, CAMELOT Investigators